Inclusion Criteria:

- Primary cerebral or oculocerebral NHL not previously treated with chemotherapy or
radiotherapy and diffuse large B-cell lymphomas, with cerebral and / or
neuromeningeal involvement at diagnosis.

- Diagnosis proved by histological or cytological examination of cerebral specimens,
CSF or vitreous humour.

- Diffuse large cell CD20+ lymphoma.

- Men or women between the ages of 18 and 60 years.

- Presence of a measurable target to evaluate response.

- Negative serological tests for HIV, hepatitis B (except in cases of vaccination),
hepatitis C.

- Life-expectancy ≥ 3 months

- Patient having given written consent to participate in this study.

Exclusion Criteria:

- CD20- lymphoma.

- History of indolent lymphoma, treated or untreated.

- Contraindication for one of the products used in polychemotherapy.

- Known hypersensitivity to mouse antibodies.

- Absence of measurable target to evaluate response.

- History of cancer in the 5 years prior to inclusion except for cutaneous basocellular
carcinomas and non-invasive carcinomas of the neck of the uterus.

- Cardiac contraindication to treatment with anthracyclines or to hyperhydration:

SEVERE DISTURBANCE OF HEART RHYTHM VENTRICULAR EJECTION FRACTION BELOW 50% HISTORY OF
RECENT MYOCARDIAL INFARCTION

- Previously known severe renal insufficiency and/or creatinaemia >150 µM/L (apart from
invasion of the kidneys by the lymphoma).

- Total bilirubin >30 µmol/L, ASAT, ALAT >2.5 times the upper normal value (apart from
invasion of the liver by the lymphoma).

- Insufficient medullary reserve: PNL < 1 G/L and platelets <100 G/L (apart from
invasion of the medulla by the lymphoma).

- History of organ transplantation or other causes of severe immunosuppression.

- Pregnant woman.

- Patient incapable of keeping to regular monitoring.